Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.
Physiotherapy and Rehabilitation Application and Research Center, Hasan Kalyoncu University, Gaziantep, Turkey.
Clin Rheumatol. 2022 Oct;41(10):3245-3252. doi: 10.1007/s10067-022-06279-9. Epub 2022 Jul 8.
On March 11, 2020, the World Health Organization, realizing the level of spread worldwide and the severity of the condition, accepted coronavirus disease 19 (COVID-19) as a pandemic. Subsequently, quarantine conditions were implemented around the world, and these triggered particular results. Like all other individuals, fibromyalgia syndrome (FMS) patients were affected by these conditions. The stress load in pandemic conditions, difficulties in accessing healthcare services, changes in exercise compliance, variations in physiotherapy programs, and remote work conditions all had an impact on FMS patients. Although general expectations were negative, some FMS patients were able to manage the pandemic conditions and even turn them in their favor. This is thought to be due to this patient group having established strategies to cope with stress in the pre-pandemic period, and they had sufficient ability to adapt to changing situations. FMS-related symptoms occur in a subset of individuals following COVID-19. One of the factors is the increased psychological burden after COVID-19. There is evidence that neuroinflammatory pathways affect neuroplasticity in the central nervous system and trigger the onset of FMS-related symptoms. Among the probable mechanisms are alterations in inflammatory and anti-inflammatory pathways. Changes in the autonomic nervous system with the effect of SARS-CoV-2 may induce the emergence of FMS-related symptoms. FMS and COVID-19 can coexist, and FMS may create a tendency to vaccine hesitancy. Future studies should focus on elucidating FMS-related symptoms occurring post-COVID-19. There is a need to determine distinctions between the FMS clinical status that emerged following COVID-19 and the regular patient group in terms of diagnosis, treatment, and follow-up.
2020 年 3 月 11 日，世界卫生组织意识到全球传播水平和疾病严重程度，将 2019 冠状病毒病（COVID-19）认定为大流行。随后，全球实施了隔离措施，这些措施产生了特殊的影响。与所有其他人一样，纤维肌痛综合征（FMS）患者也受到了这些情况的影响。大流行条件下的压力负荷、获得医疗保健服务的困难、锻炼合规性的变化、物理治疗方案的变化以及远程工作条件都对 FMS 患者产生了影响。尽管普遍预期是负面的，但一些 FMS 患者能够应对大流行条件，甚至使其对自己有利。这被认为是由于该患者群体在大流行前就已经建立了应对压力的策略，并且他们有足够的能力适应不断变化的情况。COVID-19 后，一部分人会出现与 FMS 相关的症状。其中一个因素是 COVID-19 后心理负担增加。有证据表明，神经炎症途径会影响中枢神经系统的神经可塑性，并引发与 FMS 相关的症状。可能的机制之一是炎症和抗炎途径的改变。SARS-CoV-2 对自主神经系统的影响可能会引发与 FMS 相关的症状。FMS 和 COVID-19 可以共存，并且 FMS 可能会导致对疫苗的犹豫不决。未来的研究应集中阐明 COVID-19 后出现的与 FMS 相关的症状。需要确定 COVID-19 后出现的 FMS 临床状况与常规患者群体在诊断、治疗和随访方面的区别。
